Micell Technologies is an innovative technology company dedicated to transforming medical devices for improved patient outcomes. The Company’s supercritical fluid technology is a key component in its enhanced drug delivery system, which is currently in use within the interventional cardiology market, though the technology has potentially far-reaching applications for treating cardiovascular disease. Focused on eliminating some of the primary limitations typical of existing technologies used to create drug-eluting medical devices, Micell is committed to bringing this unique approach to market.
The Company’s flagship product, MiStent®, is a CE-marked drug-eluting stent that is currently available for sale in many countries around the world. In Europe, MiStent can be purchased through our distribution partner, STENTYS. MiStent is not approved for sale or use within the United States. Click here for more information on MiStent or here for more information on international distribution partners.
To sign up for regular corporate updates, please click here.
Micell Technologies, Inc. is a member of AdvaMed and has adopted the AdvaMed Code of Ethics.